胃癌组织中抑癌基因RUNX3和CHFR启动子异常甲基化的临床意义

目的检测胃癌患者肿瘤组织中RUNX3和CHFR基因启动子区域甲基化状态,并探讨它们甲基化状态的改变与胃癌临床病理特征的关系。方法收集61例胃癌患者的肿瘤组织标本,胃癌患者术前均未行放疗和化疗。采用甲基化特异性PCR方法 (MSP法)检测RUNX3、CHFR基因启动子区的甲基化状态。分析这两个基因甲基化与胃癌患者临床病理特征之间的关系。结果 54.0%和40.9%的胃癌组织中分别存在RUNX3和CHFR基因启动子的异常甲基化,在≥5cm的胃癌组织中,RUNX3和CHFR的甲基化频率分别显著高于它们在<5cm胃癌组织的甲基化频率;RUNX3和CHFR基因的异常甲基化与其他临床病理特征如年龄、性别、病理分期、浸润深度、组织分化程度以及淋巴结转移无相关性。结论 RUNX3和CHFR基因的甲基化状态可作为评估胃癌患者临床病理特征的分子标志物。

Clinical significance of aberrant promoter methylation of RUNX3 and CHFR genes in Gastric Cancer tissues

Objective To detect promoter methylation of RUNX3 and CHFR genes in cancer tissues from gastric cancer （GC） patients,and analyze the relationship between promoter methylation of RUNX3 and CHFR genes and clinicopathological features in GC.Methods A total of 123 GC patients who were diagnosed as primary GC without receiving any radiotherapy and chemotherapy were collected.After surgical resections,the cancer tissues were collected.Methylation-specific polymerase chain reaction （MSP） was used to detect the promoter methylation status of RUNX3 and CHFR genes from these specimens.Results The positive rate of aberrant promoter methylation of RUNX3 and CHFR genes were 54.0% and 40.9% in GC specimens respectively.The frequencies of RUNX3 and CHFR methylation in tumor size≥5cm were significantly higher than those in tumor size 5cm （PRUNX3=0.019,PCHFR=0.017）.No significant relationship was found between RUNX3 and CHFR methylation and other clinicopathological features including the age,gender,stage of pathology,tumor invasion depth,tumor differentiation and the involvement of lymph node.Conclusion The methylation status of RUNX3 and CHFR genesbe could be used as biomarkers for the prediction of clinic pathlogical features in GC.